首页> 外文OA文献 >1 The Interim 18-FDG-PET/CT Failed to Predict the Outcome in Diffuse Large B-Cell Lymphoma Patients Treated at the Diagnosis with Rituximab-CHOP Short title: Interim PET does not predict the outcome in DLBCL

【2h】

1 The Interim 18-FDG-PET/CT Failed to Predict the Outcome in Diffuse Large B-Cell Lymphoma Patients Treated at the Diagnosis with Rituximab-CHOP Short title: Interim PET does not predict the outcome in DLBCL

机译：1临时18-FDG-pET / CT未能预测利妥昔单抗-CHOp诊断治疗弥漫性大B细胞淋巴瘤患者的结果简称：临时pET不能预测DLBCL的结果

页面导航

著录项
相似文献
相关主题

著录项

作者
Patrizia Pregno; Marilena Bellò; Barbara Botto; Silvia Franceschetti; Francesca Giunta; Marco Ladetto; Massimo Menga; Maura Nicolosi; Giorgio Priolo; Benedetta Puccini; Luigi Rigacci; Flavia Salvi; Luca Vaggelli; Roberto Passera; Gianni Bisi; Umberto Vitolo; Florence Hematology; Ss Antonio; Cesare Arrigo Hospital;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP [J] . PregnoP., ChiappellaA., BellòM., Blood: The Journal of the American Society of Hematology . 2012,第9期

机译：中期18-FDG-PET / CT无法预测利妥昔单抗-CHOP治疗后弥漫性大B细胞淋巴瘤患者的结局
2. Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods [J] . E Malek, A Sendilnathan, M Yellu, Blood cancer journal. . 2015,第7期

机译：与弥散性大B细胞淋巴瘤相比，中期PET上的代谢肿瘤体积比半定量方法更好地预测结局
3. Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment [J] . González-BarcaE., CanalesM., CortésM., Nuclear Medicine Communications . 2013,第10期

机译：IIF试验以六个周期的R-CHOP-14加培格非司汀作为一线治疗，在II期试验中均相治疗的弥漫性大B细胞淋巴瘤患者中，临时18F-FDG-PET / CT对无事件生存的预测价值
4. Prediction of diffuse large B-cell lymphoma outcome based on genes' analysis by use of SOM [C] . Furukawa, M., Watanabe, . 2005

机译：基于SOM基因分析的弥漫性大B细胞淋巴瘤预后预测
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods [O] . E Malek, A Sendilnathan, M Yellu, 2015

机译：与弥散性大B细胞淋巴瘤相比中期PET上的代谢肿瘤体积比半定量方法更好地预测结局
7. Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP [O] . Kazuhiro Kitajima, Masaya Okada, Kyoko Yoshihara, 2019

机译：用R-Chec弥漫性大B细胞淋巴瘤患者临时FDG-PET / CT发现的预测值

1 The Interim 18-FDG-PET/CT Failed to Predict the Outcome in Diffuse Large B-Cell Lymphoma Patients Treated at the Diagnosis with Rituximab-CHOP Short title: Interim PET does not predict the outcome in DLBCL

著录项

相似文献

相关主题

期刊订阅